LENZ Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for LENZ Therapeutics, Inc. (LENZ) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021
Period EndingDec 2024Dec 2023Dec 2022Dec 2021
Operating Activities
Net Income-49.77-69.97-101.05-7.56
Depreciation & Amortization0.060.020.750.00
Stock Based Compensation6.371.340.720.20
Change in Working Capital-13.099.41-2.921.15
Change in Accounts Payable-4.280.864.300.38
Change in Other Working Capital-8.818.551.720.77
Other Operating Activities-2.95-0.1214.130.82
Net Cash from Operating Activities-59.39-60.38-4.09-5.39
Investing Activities
Capital Expenditures-0.47-0.036.59-0.01
Purchases of Investments-241.91-29.590.000.00
Sales/Maturities of Investments87.90-29.59-235.270.00
Net Cash from Investing Activities-154.48-29.62-0.04-0.01
Financing Activities
Common Stock Issued79.510.200.66251.63
Other Financing Activities119.49-2.48-0.080.00
Net Cash from Financing Activities199.0080.7030.2622.77
Summary
Net Change in Cash-14.87-9.3026.1317.36
Cash at Beginning of Period35.1444.4418.310.95
Cash at End of Period20.27-90.0047.7318.31
Free Cash Flow-59.86-60.41-94.57-5.40